Schizophrenia Research
Volume 77, Issue 2 , Pages 215-227 , 15 September 2005

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection

  • Robert A. Lasser

      Affiliations

    • Global Medical Strategy, Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ 08869, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 908 927 3490; fax: +1 908 252 0912.
    • ,
  • Cynthia A. Bossie

      Affiliations

    • Medical Affairs Division, Janssen Pharmaceutica Products, L.P., 1125 Trenton-Harbourton Road, Office A20305, Titusville, NJ 08560-0200, USA
    • ,
  • Georges M. Gharabawi

      Affiliations

    • Medical Affairs Division, Janssen Pharmaceutica Products, L.P., 1125 Trenton-Harbourton Road, Office A20305, Titusville, NJ 08560-0200, USA
    • ,
  • John M. Kane

      Affiliations

    • The Zucker Hillside Hospital, 5-59 263rd Street, Glen Oaks, NY 11004, USA

Received 23 August 2004 ,Revised 3 March 2005 ,Accepted 14 March 2005.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. fourth ed.. Washington, DC: American Psychiatric Association; 1994;
  2. Amminger GP, Resch F, Mutschlechner R, Friedrich MH, Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur. Child Adolesc. Psychiatry. 1997;6:212–218
  3. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry. 2005;162:441–449
  4. Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J. Clin. Psychiatry. 1987;48:94–97
  5. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry. 2004;161:414–425
  6. Csernansky JG, Mahmoud R, Brenner R Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002;346:16–22Erratum in: N. Engl. J. Med. 2002, 346, 1424
  7. Curtis CE, Calkins ME, Grove WM, Feil KJ, Iacono WG. Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree biological relatives. Am. J. Psychiatry. 2001;158:100–106
  8. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 2003;60:553–564
  9. Dencker SJ. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J. Clin. Psychiatry. 1984;45(5 Pt 2):22–27
  10. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am. J. Psychiatry. 2002;159:103–108Erratum in: Am. J. Psychiatry. 2002, 159, 514
  11. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J. Clin. Psychiatry. 2003;64(Suppl 15):40–45
  12. Eaton WW, Thara R, Federman E, Tien A. Remission and relapse in schizophrenia: the Madras longitudinal study. J. Nerv. Ment. Dis. 1998;186:357–363
  13. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry. 2003;64:1250–1257
  14. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry. 1991;48:851–855
  15. Ho BC, Andreasen NC, Flaum M, Nogooulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am. J. Psychiatry. 2000;157:808–815
  16. Kane JM. Extrapyramidal side effects are unacceptable. Eur. Neuropsychopharmacol. 2001;11(Suppl 4):S397–S403
  17. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur. Neuropsychopharmacol. 1998;8:55–66
  18. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am. J. Psychiatry. 2002;159:554–560
  19. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry. 2003;160:1125–1132
  20. Lam YF, Velligan DI, DiCocco M, Ereshefsky L, Maples N, Castillo D, et al. Comparative assessment of antipsychotic adherence by concentration monitoring, pill count and self-report. Schizophr. Res. 2003;60:313
  21. Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J. Affect. Disord. 2004;83:263–275
  22. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur. Psychiatr. 2004;19:219–225
  23. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvements in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int. J. Neuropsychopharmacol. 2005;30:1–12
  24. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry. 2003;160:1209–1222
  25. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a challenge for the 21st century. Int. Rev. Psychiatry. 2002;14:245–255
  26. Liberman RP, Kopelowicz A, Ventura J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int. Rev. Psychiatry. 2002;14:256–272
  27. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry. 1993;50:369–376
  28. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry. 1997;58:538–546Erratum in: J. Clin. Psychiatry. 1998, 59, 200
  29. Ninan P. Generalized anxiety disorder: why are we failing our patients?. J. Clin. Psychiatry. 2001;62(Suppl 19):3–10
  30. van Os J, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int. Clin. Psychopharmacol. 2004;19:229–232
  31. Ware J, Snow K, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute; 1993;
  32. Yen CF, Chen CS, Yeh ML, Yen JY, Ker JH, Yang SJ. Comparison of insight in patients with schizophrenia and bipolar disorder in remission. J. Nerv. Ment. Dis. 2002;190:847–849

PII: S0920-9964(05)00116-7

doi: 10.1016/j.schres.2005.03.006

Schizophrenia Research
Volume 77, Issue 2 , Pages 215-227 , 15 September 2005

Article Tools

* Image Usage & Resolution